EU approval for Keytruda in head and neck cancer
The European Commission has approved MSD’s Keytruda (pembrolizumab) as monotherapy or as part of a combination, for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
The regulatory body says that the approval was based on data from the Phase III KEYNOTE-048 trial, in which the drug, compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), demonstrated a significant improvement in overall survival (OS) as monotherapy and in combination with platinum and 5-fluorouracil (5-FU) chemotherapy. Read more...
Tipifarnib Yields 100% Disease Control in HRAS-Mutant Head and Neck Squamous Cell Carcinoma
The signal transduction inhibitor (STI) tipifarnib induced disease control in all patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC) and a high variant allele frequency (VAF), according to preliminary results of a phase II trial presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.1
“We have compelling antitumor activity in the heavily pretreated cohort of patients with recurrent metastatic head and neck cancer with HRAS mutations,” Alan L. Ho, MD, PhD, Geoffrey Beene Junior Faculty Chair at Memorial Sloan Kettering Cancer Center in New York, New York, said during a presentation of the data. “This occurred regardless of previous progression on chemotherapy, immunotherapy, and cetuximab.” Read more...
UAB launching Sullivan Survivor Program for head and neck cancer in 2020